AI Insight
Researchers tested an automated AI system for prostate cancer Gleason grading on 298 whole-slide images from 274 patients, applying it without any customization to data from institutions it had never encountered before. The automated grading matched expert pathologist assessments (86% agreement within one grade group) and predicted disease recurrence comparably to clinical grading, with no statistically significant difference in prognostic accuracy. The system worked on radical prostatectomy specimens despite being trained primarily on needle biopsy samples, demonstrating robust generalization across different tissue types and hospital sites.
Why it matters
This demonstrates that AI grading systems can work reliably on real-world data from new hospitals without requiring site-specific adjustments or pathologist oversight, a critical requirement for practical deployment. The approach could enable standardized, reproducible cancer grading across large research cohorts and clinical settings where expert pathology resources are limited.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Automated Gleason grading now matches expert pathologists on the cohorts where systems are developed and tuned, but deployment-relevant gaps remain: whether an automated grade, applied without site-specific tuning or pathologist oversight, stratifies outcome comparably to expert grading on slides from unseen institutions and in cross-specimen applications. We tested this for disease-free interval (DFI), a curated recurrence endpoint. A production gland-level prostate diagnostic (PathTools Prostate v11.0) was applied frozen and uncalibrated to 298 diagnostic whole-slide images from 274 TCGA-PRAD radical-prostatectomy patients, a cohort outside its development distribution and needle-core-biopsy training data, contributed by 25 source sites under heterogeneous digitization; tissue was detected automatically with no expert region annotation. From the output we derived an ISUP grade group and continuous high-grade content, and evaluated each grade as a standalone predictor of DFI (24 events) by Harrell’s c-index with 95% bootstrap confidence intervals, a paired between-method bootstrap, and Kaplan-Meier curves with the log-rank test. The automated grade reproduced the clinical grade group at quadratic-weighted kappa = 0.62 (95% CI 0.53-0.70; 48% exact, 86% within one group), within the expert inter-observer range. As the sole predictor it stratified recurrence (log-rank p = 0.022; c-index 0.69, 95% CI 0.58-0.79), and the continuous high-grade fraction was robustly prognostic (hazard ratio 1.37 per SD, p = 0.029; c-index 0.71, 0.61-0.81). Standalone discrimination was not statistically separable from the clinical grade (c-index 0.78, 0.69-0.86; paired {triangleup} c-index spanning zero), and in a joint model the automated grade added nothing beyond it, consistent with both measuring a shared morphological axis. From a single out-of-distribution slide with no pathologist oversight, the automated grade provides standalone recurrence stratification not statistically separable from whole-gland expert grading, demonstrating robust generalizability beyond training data; reported as a continuous high-grade fraction, it offers reproducible, expert-free, grade-equivalent risk stratification for harmonizing large archival or genomically-profiled cohorts.